Eli Lilly (NYSE:LLY) Announces Positive Phase 2 Results For siRNA Therapy Amid 6% Quarterly Price Dip
Eli Lilly (NYSE:LLY) has recently announced several developments, including positive Phase 2 results for their siRNA therapy ...
Eli Lilly Phase 2 Lipoprotein(a) Study Hits Primary Endpoint
Eli Lilly on Sunday said the Phase 2 study of lepodisiran, designed to lower the production of lipoprotein (a), or lp (a), met its primary endpoint, reducing lp (a) levels by an average of 93.9% over ...
Eli Lilly sues two pharmacies making copycat Zepbound, Mounjaro
Eli Lilly is suing Strive Pharmacy and Empower Pharmacy for compounding tirzepatide, the active ingredient in Zepbound and ...
Business Insider8d
Eli Lilly announces Phase 2 trial of lepodisiran met primary endpoint
Eli Lilly (LLY) and Company announced positive Phase 2 results for lepodisiran, an investigational small interfering RNA, siRNA, therapy designed to lower the production of lipoprotein ...
Morningstar7d
Eli Lilly Phase 2 Lipoprotein(a) Study Hits Primary Endpoint
Eli Lilly on Sunday said the Phase 2 study of lepodisiran, designed to lower the production of lipoprotein(a), or lp(a), met its primary endpoint, reducing lp(a) levels by an average of 93.9% over ...